Innate Pharma (IPHA) Accounts Payables (2017 - 2025)

Innate Pharma (IPHA) has reported Accounts Payables for 9 consecutive years, with $17.1 million the latest figure, recorded in Q4 2025.

• Quarterly Accounts Payables fell 6.03% year-over-year to $17.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.1 million (down 6.03% YoY) and the FY2025 annual result came in at $17.1 million, down 6.03% from the prior year.
• Accounts Payables advanced to $17.1 million in Q4 2025 per IPHA's latest filing, from $13.7 million in the prior quarter.
• Over the last five years, Accounts Payables for IPHA reached as high as $32.5 million in Q4 2021 and fell as low as $13.7 million in Q2 2025.
• A 5-year average of $20.5 million and a median of $19.4 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables sank 99.93% — and 2022, when it advanced 9.64%.
• Year by year, Accounts Payables stood at $32.5 million in 2021, then decreased by 26.82% to $23.8 million in 2022, then decreased by 18.62% to $19.4 million in 2023, then fell by 5.94% to $18.2 million in 2024, then decreased by 6.03% to $17.1 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $17.1 million, $13.7 million, and $18.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.